Conbercept
drugOn this page
Also known as KH-902Kh902
Summary
Conbercept (CHEMBL2108313) is a phase-3 clinical-stage protein; indicated across 6 conditions including age-related macular degeneration and degenerative myopia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 6 conditions
- Clinical trials: 22
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108313 |
| Name | Conbercept |
| Type | Protein |
| Max phase | 3 |
Also known as: Conbercept, KH-902, Kh902, CONBERCEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| degenerative myopia | 3 | MONDO:0001383 | EFO:0004207 |
| retinal vein occlusion | 2 | MONDO:0006951 | EFO:1001157 |
| wet macular degeneration | 2 | MONDO:0005417 | EFO:0004683 |
| retinoblastoma | 2 | MONDO:0008380 | MONDO:0008380 |
| corneal neovascularization | 1 | MONDO:0006713 | EFO:1000880 |
Clinical trials
Total trials: 22.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 6 |
| PHASE2 | 5 |
| Not specified | 5 |
| EARLY_PHASE1 | 3 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06305143 | PHASE4 | ACTIVE_NOT_RECRUITING | Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy |
| NCT02577107 | PHASE4 | COMPLETED | Head to Head Study of Anti-VEGF Treatment. |
| NCT02802657 | PHASE4 | UNKNOWN | Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata of Conbercept in Age-related Macular Degeneration |
| NCT02816710 | PHASE4 | COMPLETED | Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy |
| NCT02821520 | PHASE4 | COMPLETED | Initial Versus Delayed PDT Combination With Conbercept in PCV |
| NCT03159884 | PHASE4 | UNKNOWN | The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) |
| NCT01809223 | PHASE3 | UNKNOWN | A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV |
| NCT02194634 | PHASE3 | UNKNOWN | Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) |
| NCT01324869 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME) |
| NCT01809236 | PHASE2 | UNKNOWN | Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion |
| NCT02098720 | PHASE2 | UNKNOWN | An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD) |
| NCT02857517 | PHASE2 | UNKNOWN | Intravitreal Conbercept for Idiopathic Choroidal Neovascularization |
| NCT02934841 | PHASE2 | UNKNOWN | Conbercept in Choroidal Neovascularization Secondary to Uveitis |
| NCT04782115 | PHASE2 | COMPLETED | Evaluation of RC28-E Injection in Diabetic Macular Edema |
| NCT03426540 | EARLY_PHASE1 | COMPLETED | Intravitreal Conbercept After Vitrectomy |
| NCT03571282 | EARLY_PHASE1 | UNKNOWN | Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma |
| NCT03973125 | EARLY_PHASE1 | UNKNOWN | Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma |
| NCT06717412 | Not specified | RECRUITING | Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy |
| NCT03863535 | Not specified | UNKNOWN | PRP vs PRP+IVC for Severe nPDR |
| NCT04627402 | Not specified | UNKNOWN | Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) |
| NCT05222633 | Not specified | UNKNOWN | Anti-VEGF in Real-world |
| NCT05229237 | Not specified | COMPLETED | Conbercept for Polypoidal Choroidal Vasculopathy（START Study） |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).